Search results for "PLACEBO"

showing 10 items of 704 documents

Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomized, double blind, placebo controlled, phase III study.

2015

Objective To assess the efficacy of recombinant human erythropoietin (rhEPO) in amyotrophic lateral sclerosis (ALS). Methods Patients with probable laboratory-supported, probable or definite ALS were enrolled by 25 Italian centres and randomly assigned (1:1) to receive intravenous rhEPO 40 000 IU or placebo fortnightly as add-on treatment to riluzole 100 mg daily for 12 months. The primary composite outcome was survival, tracheotomy or >23 h non-invasive ventilation (NIV). Secondary outcomes were ALSFRS-R, slow vital capacity (sVC) and quality of life (ALSAQ-40) decline. Tolerability was evaluated analysing adverse events (AEs) causing withdrawal. The randomisation sequence was computer-…

MaleGastroenterologylaw.inventionRandomized controlled triallaw1506Amyotrophic lateral sclerosisMOTOR NEURON DISEASEeducation.field_of_studyRecombinant ProteinMiddle AgedRecombinant ProteinsTreatment OutcomePsychiatry and Mental HealthNeuromuscularSettore MED/26 - NeurologiaFemaleerythropoietyn clinical trialmedicine.drugHumanALS; MOTOR NEURON DISEASE; Adult; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Erythropoietin; Female; Humans; Male; Middle Aged; Recombinant Proteins; Treatment OutcomeAdultmedicine.medical_specialtyPopulationSocio-culturalePlaceboDouble blindALS; erythropoietyn clinical trialDouble-Blind MethodArts and Humanities (miscellaneous)ALS; MOTOR NEURON DISEASE; Adult; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Epoetin Alfa; Erythropoietin; Female; Humans; Male; Middle Aged; Recombinant Proteins; Treatment Outcome; Neurology (clinical); Psychiatry and Mental Health; Surgery; Arts and Humanities (miscellaneous)Internal medicinemedicineALS; MOTOR NEURON DISEASEHumanseducationErythropoietinAgedbusiness.industryAmyotrophic Lateral SclerosisEpoetin alfamedicine.diseaseSurgeryClinical trialEpoetin AlfaErythropoietinSurgeryNeurology (clinical)ALSbusinessAmyotrophic Lateral Sclerosi
researchProduct

Liraglutide and cardiovascular outcomes in type 2 diabetes

2016

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The primary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcome, with a margin of 1.30 for the upper boundary of the 95% confidence interval of the hazard ratio. No adjus…

MaleGastrointestinal DiseasesTreatment outcomeClinical BiochemistryMyocardial InfarctionType 2 diabetes030204 cardiovascular system & hematologylaw.inventionMedicine; Endocrinology0302 clinical medicineRandomized controlled trialAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome; Medicine (all)lawCardiovascular DiseaseClinical-trial; Pancreatitis; Therapies; Cancer; Drugs11 Medical and Health SciencesResearch Support Non-U.S. Gov'tMedicine (all)PANCREATITISHazard ratioLEADER Steering CommitteeFollow up studiesGeneral MedicineMiddle AgedAlbiglutideMulticenter StudyStrokeTRIALSTreatment OutcomeCardiovascular DiseasesRandomized Controlled TrialFemaleLife Sciences & BiomedicineCardiovascular outcomesmedicine.drugHumanmedicine.medical_specialtyGastrointestinal DiseaseMEDLINE030209 endocrinology & metabolismLEADER Trial InvestigatorsPlaceboFollow-Up Studie03 medical and health sciencesMedicine General & InternalResearch Support N.I.H. ExtramuralDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicinemedicineJournal ArticleHumansHypoglycemic AgentsAgedGlycemic efficacyScience & TechnologyHypoglycemic AgentLiraglutidebusiness.industrySemaglutideLiraglutidemedicine.diseaseSurgeryDiabetes Mellitus Type 2businessFollow-Up Studies
researchProduct

Effects of a preparation containing a standardized ginseng extract combined with trace elements and multivitamins against hepatotoxin-induced chronic…

1987

A preparation containing a standardized ginseng extract which has been shown to exert anti-hepatotoxic activity in vitro, combined with trace elements and multi-vitamins was compared to placebo in 24 elderly out-patients with toxin-induced (alcohol and drugs) chronic liver disease in order to evaluate its effect on liver function. Each patient was blindly treated either with the preparation containing ginseng extract or placebo for 12 weeks. The preparation containing ginseng extract significantly modified bromsulphthalein retention and blood zinc levels when compared to pre-treatment levels and to placebo. Serum bile acids, and γ-glutamyl transpeptidase before and after a fatty meal were …

MaleGinsenosidesmedicine.medical_treatment030204 cardiovascular system & hematologyPharmacologyChronic liver diseaseBiochemistrylaw.inventionGinsengRandom Allocation0302 clinical medicineRandomized controlled triallawClinical Trials as TopicLiver DiseasesHepatotoxinGeneral MedicineVitaminsgamma-GlutamyltransferaseMiddle AgedZincLiver030220 oncology & carcinogenesisDrug Therapy CombinationFemaleChemical and Drug Induced Liver Injurymedicine.medical_specialtyPanaxPlaceboBile Acids and Salts03 medical and health sciencesPharmacotherapyDouble-Blind MethodInternal medicinemedicineHumansAgedChemotherapyPlants Medicinalbusiness.industryBiochemistry (medical)Cell BiologySaponinsmedicine.diseaseDietary FatsTrace ElementsEndocrinologyChronic DiseaseLiver functionbusiness
researchProduct

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-…

2017

Background Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes. Methods DEPICT-1 was a double-blind, randomised, parallel-controlled, three-arm, phase 3, multicentre study done at 143 sites in 17 countries. Eligible patients were aged 18–75 years and had inadequately controlled type 1 diabetes (HbA1c between ≥7·7% and ≤11·0% [≥61·0 mmol/mol and ≤97·0 mmol/mol]) and had been prescribed insulin for at least 12 months before enrolment. After an 8 week lead-in period to optimise diabetes man…

MaleGlycated Hemoglobin AEndocrinology Diabetes and MetabolismType 2 diabetes030204 cardiovascular system & hematologySettore MED/13 - Endocrinologialaw.inventionchemistry.chemical_compound0302 clinical medicineEndocrinologydiabetes dapaglifozinGlucosidesRandomized controlled triallawInsulin03.02. Klinikai orvostanDapagliflozinMiddle AgedDiabetes and MetabolismTreatment OutcomeCombinationDrug Therapy CombinationFemaleType 1Adultmedicine.medical_specialtyDiabetic ketoacidosis030209 endocrinology & metabolismPlacebo03 medical and health sciencesDrug TherapyDiabetes managementDiabetes mellitusInternal medicineDiabetes MellitusInternal MedicinemedicineHumansHypoglycemic AgentsBenzhydryl CompoundsAdult; Benzhydryl Compounds; Body Weight; Diabetes Mellitus Type 1; Drug Therapy Combination; Female; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment OutcomeAdult; Benzhydryl Compounds; Body Weight; Diabetes Mellitus Type 1; Drug Therapy Combination; Female; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome; Internal Medicine; Endocrinology Diabetes and Metabolism; EndocrinologyGlycated HemoglobinType 1 diabetesbusiness.industryBody Weightmedicine.diseaseHypoglycemiaSurgeryDiabetes Mellitus Type 1chemistrybusinessThe Lancet Diabetes & Endocrinology
researchProduct

Dexketoprofen/tramadol: randomised double-blind trial and confirmation of empirical theory of combination analgesics in acute pain

2015

Background Combination analgesics are effective in acute pain, and a theoretical framework predicts efficacy for combinations. The combination of dexketoprofen and tramadol is untested, but predicted to be highly effective. Methods This was a randomised, double-blind, double-dummy, parallel-group, placebo-controlled, single-dose trial in patients with moderate or severe pain following third molar extraction. There were ten treatment arms, including dexketoprofen trometamol (12.5 mg and 25 mg) and tramadol hydrochloride (37.5 mg and 75 mg), given as four different fixed combinations and single components, with ibuprofen 400 mg as active control as well as a placebo control. The study objecti…

MaleKetoprofenWisdom toothEmpirical Researchlaw.inventionPostoperative painDolor postoperatoriRandomized controlled triallawDose rangeAntiinflammatory agentsTromethamineTramadolRandomised controlled trialAnalgesicsAnti-Inflammatory Agents Non-SteroidalAgents antiinflamatorisQueixal del senyGeneral MedicineMiddle AgedIbuprofenAcute PainAnalgesics OpioidKetoprofenAnesthesiaTramadol HydrochlorideDrug Therapy CombinationFemaleTramadolResearch Articlemedicine.drugAdultAdolescentAnalgesicClinical NeurologyPlaceboOdontologiaYoung AdultAnalgèsicsDouble-Blind MethodThird molarPosologymedicineDexketoprofenHumansPain ManagementCombination analgesicsbusiness.industryDexketoprofenPosologiaAnesthesiology and Pain MedicineDentistryNeurology (clinical)Analgesiabusiness
researchProduct

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

2013

International audience; BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. METHODS: We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg onc…

MaleMESH: Factor Xa[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRivaroxabanRandomized controlled triallawMedicineMESH: Double-Blind Method030212 general & internal medicineMESH: AgedMESH: Middle AgedVenous ThromboembolismGeneral MedicineMiddle AgedMESH: Thiophenes3. Good healthAnesthesiaAcute DiseaseMESH: Administration OralMESH: Acute DiseaseFemaleMESH: Hemorrhagemedicine.drugAdultRandomizationMESH: EnoxaparinInjections SubcutaneousMorpholinesMESH: MorpholinesHemorrhageThiophenesMESH: AnticoagulantsMESH: Drug Administration SchedulePlaceboDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodRivaroxaban venous thromboembolismHumansEnoxaparinAgedRivaroxabanMESH: Humansbusiness.industryMESH: Injections SubcutaneousAnticoagulantsMESH: AdultConfidence intervalMESH: MalechemistryBetrixabanRelative riskbusinessVenous thromboembolismMESH: FemaleFactor Xa Inhibitors
researchProduct

Effectiveness of a spray containing 1% malic acid in patients with xerostomia induced by graft-versus-host disease

2018

Background To evaluate the clinical effectiveness of a topical sialogogue spray (malic acid, 1%) in the treatment of xerostomia in patients with chronic Graft versus Host Disease (cGVHD). Material and Methods This study was designed as a randomized double-blind clinical study. Twenty-eight patients with cGVHD suffering from xerostomia were divided into 2 groups: the first group (14 patients) received a topical sialagogue spray containing malic acid 1% (SalivAktive®) whereas the second group (14 patients) received a placebo. Both groups received treatment for 2 weeks. Dry Mouth Questionnaire (DMQ) scores and unstimulated salivary flows rate were collected before and after treatment. Results …

MaleMalatesGraft vs Host DiseaseGastroenterologylaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawSurveys and QuestionnairesMalic acidSialogogueMalic acid; Transplantation; XerostomiaOtorhinolaryngology2734 Pathology and Forensic MedicineMiddle AgedMedically compromised patients in Dentistry:CIENCIAS MÉDICAS [UNESCO]Treatment OutcomeUNESCO::CIENCIAS MÉDICASFemalemedicine.symptomOral SpraysSalivationAdultmedicine.medical_specialtyClinical effectivenessmalic acidPlaceboXerostomia03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansIn patientSalivaGeneral DentistryTransplantationbusiness.industryResearchXerostomia; malic acid; transplantation; Surgery; Otorhinolaryngology2734 Pathology and Forensic Medicine; Dentistry (all)030206 dentistrymedicine.diseaseDry mouthGraft-versus-host diseaseOtorhinolaryngologychemistryDentistry (all)SurgeryMalic acidbusinesstransplantation
researchProduct

Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)…

2015

AbstractThe polyphenol quercetin may prevent CVD due to its antihypertensive and vasorelaxant properties. We investigated the effects of quercetin after regular intake on blood pressure (BP) in overweight-to-obese patients with pre-hypertension and stage I hypertension. In addition, the potential mechanisms responsible for the hypothesised effect of quercetin on BP were explored. Subjects (n 70) were randomised to receive 162 mg/d quercetin from onion skin extract powder or placebo in a double-blinded, placebo-controlled cross-over trial with 6-week treatment periods separated by a 6-week washout period. Before and after the intervention, ambulatory blood pressure (ABP) and office BP were m…

MaleMedicine (miscellaneous)Blood PressureBody Mass IndexPrehypertensionchemistry.chemical_compoundOnionsInsulinheterocyclic compoundsCross-Over StudiesNutrition and DieteticsbiologyFull PapersBlood Pressure Monitoring AmbulatoryMiddle AgedCardiovascular diseasesC-Reactive ProteinCholesterolTreatment OutcomeHypertensionBody CompositionQuercetinFemaleWaist CircumferenceQuercetinHuman and Clinical NutritionAdultmedicine.medical_specialtyMean arterial pressureAmbulatory blood pressurePlaceboPrehypertensionDouble-Blind MethodInternal medicinemedicineHumansObesityAntihypertensive AgentsTriglyceridesAgedPlant Extractsbusiness.industryBody WeightEndothelial functionAngiotensin-converting enzymeOverweightEndocrinologyBlood pressurechemistryDietary Supplementsbiology.proteinPatient ComplianceEndothelium VascularEnergy IntakeAsymmetric dimethylargininebusinessBiomarkersBritish Journal of Nutrition
researchProduct

Effect of the local administration of betamethasone on pain, swelling and trismus after impacted lower third molar extraction. A randomized, triple b…

2013

Objectives: The aim of this study is to compare the analgesic and anti-inflammatory effects of the local postoperative administration of a single 12-mg dose of betamethasone after the surgical removal of impacted lower third molars. Study Design: A split-mouth, triple-blind, randomized, placebo-controlled clinical trial of 25 patients requiring the surgical removal of symmetrical lower third molars was performed. In the experimental side, a 12-mg dose of betamethasone was administered submucosally after the surgical procedure, while in the control side a placebo (sterile saline solution) was injected in the same area. To assess postoperative pain, visual analogue scales and the consumption …

MaleMolarAdministration TopicalAnti-Inflammatory AgentsTrismusBetamethasonelaw.inventionPostoperative ComplicationsClinical trialsRandomized controlled triallawEdemaAntiinflammatory agentsEdemaTeeth extractionMedicineProspective StudiesExtracció dentalPain PostoperativeAnalgesicsTooth ImpactedAgents antiinflamatorisDent molar:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludAnesthesiaUNESCO::CIENCIAS MÉDICASBetamethasoneFemaleOral Surgerymedicine.symptommedicine.drugmedicine.medical_specialtyAnalgesicOdontologíaPlaceboYoung AdultAnalgèsicsDouble-Blind MethodHumansGeneral Dentistrybusiness.industryResearchMolarSurgeryClinical trialOtorhinolaryngologyTooth ExtractionMolar ThirdTrismusSurgerybusinessAssaigs clínicsMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Effects of localmelatonin application on post-extraction sockets after third molar surgery: a pilot study

2014

Objectives: The purpose of this study was to assess the anti-inflammatory, analgesic and osteogenic early effects of melatonin on post-extraction sockets ofpatients requiring third molars extraction. Study Design: A randomized, triple-blind clinical trial was made using a split-mouth design. Both lower third molars of 10 patients were extracted and 3 mg of local melatonin or placebo were applied. Concentrations of interleukin-6 and nitrotyrosine were determined on samples of the clot from the socket by independent ELISA tests. Radiographic bone density was evaluated by measuring Hounsfield Units in panoramic and cross sections obtained by digital scanner. Statistycal analysis by Kolmogorov-…

MaleMolarBone densityAdministration TopicalRadiographyDentistryPilot ProjectsOdontologíaPlaceboMelatoninYoung Adultchemistry.chemical_compoundDouble-Blind MethodBone DensityHounsfield scalemedicineHumansTooth SocketGeneral DentistryDental alveolusMelatoninInterleukin-6business.industryResearchNitrotyrosine:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludOtorhinolaryngologychemistryTooth ExtractionUNESCO::CIENCIAS MÉDICASFemaleMolar ThirdSurgeryOral Surgerybusinessmedicine.drug
researchProduct